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Abstract
Background: This study reports our experience over the last
six years in the diagnosis of Smith-Lemli-Opitz syndrome
and other inborn errors of cholesterol biosynthesis.
Methods: Gas chromatography/mass spectrometry was used
to obtain sterol profiles in plasma and erythrocyte mem-
branes of suspected patients.
Results: Plasma sterol reference values calculated in un-
affected subjects (ns276) were in agreement with those pre-
viously reported. Among patients investigated from 2005 to
2010, we report 16 patients affected by Smith-Lemli-Opitz
syndrome, three of whom represent new cases and 13 of
whom were follow-up patients. In this period we also iden-
tified a new case of chondrodysplasia punctata 2 X-linked.
The estimated incidence obtained for Smith-Lemli-Opitz
syndrome was 1:93 suspected patients (1.08%). We also
studied the effect of storage on the dehydrocholesterols/
cholesterol ratio in plasma and erythrocyte membranes of
patients affected by Smith-Lemli-Opitz syndrome stored at
–208C for up to 22 and 20 months, respectively. A significant
negative linear correlation between storage time and the
dehydrocholesterols/cholesterol ratio was identified in both
plasma and erythrocyte membranes. The decrease in the
dehydrocholesterols/cholesterol ratio in erythrocyte mem-
branes was at least two-fold higher than in plasma.
Conclusions: The results of this study may be helpful for
diagnosis and interpretation of data in patients with findings
suggestive of a cholesterol biosynthesis defect.
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Introduction
The defects of cholesterol (CHOL) biosynthesis are inherited
disorders caused by different enzyme deficiencies in the
CHOL metabolic pathway. Patients affected by these dis-
orders have multiple morphogenic and congenital anomalies
including internal organ, skeletal and/or skin abnormalities.
They also show increased concentrations of diagnostic
metabolites in the blood and carry disease-causing mutations
in genes encoding the implicated enzymes (1). The prototype
of this group of disorders is the Smith-Lemli-Opitz syndrome
(SLOS; MIM 270400) an autosomal recessive disease caused
by a defect in 7-dehydrocholesterol reductase (EC 1.3.1.21),
the enzyme that catalyzes the last step of CHOL biosynthe-
sis. Typically, patients affected by SLOS show an accumu-
lation of 7-dehydrocholesterol (7-DHC) and its isomer
8-dehydrocholesterol (8-DHC) in blood and tissues, which is
also generally associated with a low CHOL concentration (2,
3). The human 7-dehydrocholesterol reductase gene (DHCR7)
has been cloned and localized to chromosome 11q12-13 by
Moebius et al. (4). To date, 80 mutant DHCR7 alleles have
been identified in patients affected by SLOS, and the most
frequent is the mutation IVS8-1G)C, which results in
abnormal splicing of exon 9 involving a 134 base-pair inser-
tion of intron 8 sequence, a resultant frameshift, and a pre-
mature translation stop (5, 6).
SLOS patients show a large and variable spectrum of
inherited morphogenic anomalies, including dysmorphic
craniofacial features, microcephaly, multiple internal organ,
skeletal, and urogenital malformations, growth and mental
retardation and behavioral problems. Syndactyly of the
second and third toe is the most common physical finding in
these patients. The clinical severity score of SLOS is based
on the clinical findings in 10 organs: brain, oral, acral, eye,
heart, kidney, liver, lung, bowel and genitalia (7, 8). The
clinical severity correlates negatively with the CHOL con-
centration, and positively with the concentrations of 7-DHC
and the sum of dehydrocholesterols (DHC; 7-DHCq8-DHC)
expressed as a fraction of total sterols (8, 9). The DHC frac-
tion and the DHC/CHOL ratio better express the systemic
sterol abnormality than absolute blood sterol concentrations,
which are influenced by individual variability and are only
partly dependent on the rate of endogenous CHOL synthesis
(8). Two forms of SLOS can be distinguished clinically, type
I and type II. Patients with more severe malformations and
elevated mortality rate (type II SLOS) generally show lower
total CHOL concentrations (CHOL-10 mg/dL) and higher
DHC/sterol ratios than type I SLOS patients, who have mild
malformations and a higher probability of survival (9, 10).
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A genetic distinction between type I and type II SLOS is not
widely accepted since both types can be caused by mutations
at the same genetic locus (7, 8). The clinical manifestations
of SLOS may result from CHOL deficiency or from the tox-
icity of precursor sterols, in particular 7-DHC, which is
absent or detected in only trace amounts in plasma of normal
subjects. CHOL is essential for cell membrane synthesis, reg-
ulation of membrane permeability and fluidity, and as pre-
cursor of steroid hormones and bile acids (11). CHOL is also
needed for autoprocessing (activation) of sonic hedgehog
(Shh), an important protein in early limb patterning and
craniofacial development in the embryo (12), and abnormal
Shh signaling activation may explain the malformations in
SLOS (13). Currently, most SLOS patients are treated with
dietary CHOL supplementation and early intervention may
be of benefit for the behavioral and autistic aspects of these
patients (7, 14).
The identification of the metabolic and molecular bases of
SLOS led to the discovery of other defects in post-squalene
CHOL biosynthesis, and to date 7 defects have been de-
scribed in humans (1). The incidence of SLOS is estimated
at 1 in 15,000–60,000 births in the European population (6,
15) and at 1 in 60,000 births in the USA (8), while other
defects in post-squalene CHOL biosynthesis are extremely
rare (16–23).
The biochemical diagnosis of SLOS is generally per-
formed by gas chromatography (GC) or gas chromatography
paired to mass spectrometry (GC-MS) for qualitative and
quantitative analysis of sterols, and in particular of DHC,
following reference methods published previously by Tint
et al. and Kelley (3, 24).
In this study we describe our experience over the last six
years (2005–2010) in laboratory diagnosis of SLOS and
other defects of CHOL biosynthesis by analyzing the sterol
profiles in plasma and erythrocyte membranes (EM) by GC-
MS. The sterols that we measured were CHOL and its pre-
cursors, such as 7-DHC/desmosterol, 8-DHC, lathosterol,
and exogenous sterols, such as campesterol, stigmasterol, and
sitosterol. Reference values for CHOL and other sterols were
calculated in plasma samples of unaffected subjects. Sterols
were also analyzed in the EM to confirm the suspect or
uncertain results obtained in plasma. In order to ascertain the
stability of the DHC, we evaluated storage effects on CHOL
and DHC concentrations in plasma and EM samples from
SLOS and unaffected subjects, and the correlation between
the DHC/CHOL ratio and the storage time of samples.
Materials and methods
Study population
The study population comprised 294 patients (145 males, 149
females) showing clinical findings suggestive of a CHOL bio-
synthesis defect. All samples were collected during the period from
2005 to 2010. The patients were admitted from the pediatric units
of University Hospital Federico II of Naples and pediatric units of
other Italian regions. Their ages ranged from a few days to 22 years
(mean age 2.7 years).
Specimens
Blood in EDTA (ns272) and plasma (ns22) samples were accept-
ed in our laboratory. We recommended that samples be sent in a
test tube protected from direct light to prevent 7-DHC photolysis
(25) and that they be maintained at 4–88C and not frozen. Plasma
and erythrocytes isolated from blood samples were stored at –208C
until used for analysis.
Reagents
The analytical solvents of HPLC grade, including methanol, dichloro-
methane, n-hexane, acetone, ethanol and chloroform, were obtained
from J.T.Baker (Deventer, Netherlands). Potassium hydroxide was
purchased from Merck (Merck KGaA, Darmstadt, Germany). Borate
buffer (0.03 mol/L, pH 7.4) was prepared using boric acid (Carlo
Erba Reagenti, Italy) and sodium tetraborate (Aldrich-Chemie, Ger-
many). Stock solutions of standard sterols (Sigma, St Louis, MO,
USA) were prepared in chloroform/methanol (2:1, v/v) at concen-
tration of 1 mg/mL. The internal standard (IS), 5-a-cholestane (Sig-
ma, St Louis, MO, USA), was prepared as a 50 mg/mL stock
solution.
Sample preparation
Plasma and EM sterol profiles were obtained using a GC-MS meth-
od previously described (26, 27). Briefly, plasma, buffy coat and
erythrocytes were isolated from blood after centrifugation at 1500
g for 5 min. Plasma (50 mL) was mixed with 50 mL of IS (50 mg/
mL) and hydrolyzed for 60 min at 808C in 3 mL of 1 N potassium
hydroxide in 90% ethanol. After hydrolysis, the sample was diluted
with 3 mL of distilled water and extracted three times with 3 mL
of hexane. The upper organic phases were pooled and evaporated
under a gentle stream of nitrogen at 408C. Finally, the sterols were
derivatized for 20 min at 808C in 100 mL of a mixture of
bis(trimethylsilyl)trifluoro-acetamide and pyridine (7:3) and 1 mL
of this solution was injected into the GC-MS. The EM were pre-
pared as follows: erythrocytes were washed twice with physiological
saline solution to eliminate residues of plasma. The cells were dis-
rupted with deionized water and with other mechanical techniques
(freezing-defrosting, sonication), alternating washings with borate
buffer and centrifugations at 3000 g for 15 min to remove any trace
of hemoglobin. Membranes were homogenized using a mini-potter
on ice. Extraction of sterols was performed according to the pro-
cedure described above for plasma using an aliquot of homogenate
containing at least 1 mg of total proteins measured by Bradford
method (28).
GC-MS method
GC-MS analysis was performed by a Fisons apparatus (model
GC8000/MD800) controlled by a work station using MassLab 3.4
software. An HP-1MS capillary column (25 m length, 0.2 mm I.D.,
0.33 mm film thickness) was used to separate sterols. The carrier
gas was helium with a linear velocity of 45 cm/s. Injector and trans-
fer line temperatures were fixed at 2808C. The initial temperature
of the oven was 2758C, which was increased to 3008C at a rate of
18C/min. Qualitative analysis was obtained by scanning the mass
range (SCAN mode) from m/z 50 to m/z 500, and sterol derivatives
were identified by comparing their retention times and mass spectra
with those of authentic compounds and/or those reported in two
libraries (Wiley and National Institute of Standards and Technolo-
gy). Quantitative analysis was performed by selecting specific ions
(SIM mode) for the sterols of interest at m/z , 357, 372 for 5 a-217
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cholestane; m/z , 368, 458 for CHOL; m/z , 351, 456 for 7-329 325
DHC and 8-DHC; m/z , 353, 458 for lathosterol; m/z , 382,255 343
472 for campesterol; m/z , 394, 484 for stigmasterol; and m/z255
, 396, 486 for sitosterol (quantification ions are underlined).357
Sterol concentrations (mg/dL) were obtained by interpolation of
analyte/IS peak-area ratio on calibration curves as described previ-
ously (26). For determination of 8-DHC concentration, we used the
7-DHC calibration curve, while the concentration of 19-nor-
cholestatrienol was calculated from the percentage of the peak area
obtained in SCAN mode, compared to the CHOL peak-area value.
Since both 7-DHC and desmosterol co-elute at the same retention
time, and their spectra show common ions, the quantification of
7-DHC is overestimated due to a contribution from desmosterol, but
this is relevant only in samples from subjects without SLOS.
Imprecision and inaccuracy
For each plasma sample, the CHOL concentration (mg/dL) obtained
by GC-MS method was compared to the CHOL concentration
(mg/dL) obtained using an enzymatic method (Modular; Roche,
Switzerland). In order to evaluate imprecision and inaccuracy in the
GC-MS method, a positive quality control (Pos QC) was prepared
and analyzed as follow: 50 mL of CHOL standard solution (1 g/L)
and 5 mL of 7-DHC standard solution (1 g/L) were mixed with 50
mL of IS (50 mg/mL). The solution was evaporated under a gentle
stream of nitrogen at 408C. The dry residue was derivatized and
analyzed in duplicate together to the samples. Due to the high insta-
bility of 7-DHC, the concentration of this sterol was measured by
the UV method (29) in order to adjust the theoretical concentration.
Statistical analysis
Data are reported as average, standard deviation, and percentile
(%ile). The statistical significance of differences between groups
was evaluated using the appropriate Student’s t-test and significance
was accepted at the level of p-0.05. Comparison procedures were
performed by Passing and Bablok regression, and by linear regres-
sion analysis.
Results
From the 294 patients investigated in the 2005–2010 period,
we describe 16 SLOS patients, of which 3 were new cases
and 13 were follow-up patients. In this period we also iden-
tified a new case of chondrodysplasia punctata 2 X-linked
(CDPX2; MIM 302960), and performed the follow-up on a
lathosterolosis case (MIM 607330). Figure 1 shows typical
GC-MS total ion chromatograms obtained using our method,
of an unaffected subject (A), and SLOS (B), lathosterolosis
(C) and CDPX2 (D) patients. The typical sterol profile in
the plasma of unaffected subjects shows two main peaks cor-
responding to IS and CHOL, while the typical SLOS profile
shows additional peaks corresponding to 8-DHC and 7-DHC.
Lathosterolosis and CDPX2 profiles are characterized by the
presence of lathosterol and 8(9)-cholestenol, respectively.
The peaks of diagnostic metabolites and CHOL were well
resolved in all chromatograms.
Imprecision and inaccuracy of the GC-MS method were
-10%, as evaluated by analyzing 7-DHC in Pos QC. The
CHOL levels in plasma samples of unaffected subjects meas-
ured by GC-MS were compared to those obtained using the
enzymatic method. In this comparison, enzymatic CHOL
values of SLOS patients were excluded because CHOL
oxidase shows low specificity in discriminating CHOL from
DHC and gives falsely high values (30). The results obtained
with the GC-MS CHOL method were in good agreement
with those obtained using the enzymatic method (ns276;
slope: 1.08, CI 95%: 0.978–1.182; intercept: –0.42, CI 95%:
–7.818–6.500).
The clinical findings in the study population, divided on
the basis of affected organ, are listed in Table 1. The most
common disease features were brain malformations (53%),
typical SLOS craniofacial features (41.3%) and acral defor-
mities (39.2%). The clinical features were present equally in
both males and females, and the most of individuals pre-
sented multiple SLOS clinical signs.
Plasma sterol concentrations in the 16 SLOS patients and
276 unaffected subjects are reported in Table 2. The refer-
ence values calculated in unaffected subjects, aged from 1
week to 11 years, are reported as the range from 2.5%ile to
97.5%ile for CHOL values, and up to 95%ile for other sterol
values. SLOS patients showed abnormally higher concentra-
tions of 7-DHC and 8-DHC compared to unaffected subjects.
The DHC concentrations in SLOS samples range from 5%
to 86% (average 33%) relative to total sterols, and were at
least 100-fold higher than the upper limit value (95%ile) of
unaffected subjects. Similarly, the median DHC/CHOL ratio
in SLOS patients was 0.35 and at least 150-fold higher than
the upper limit value (95%ile) of unaffected subjects. In
addition to DHC, a sterol artifact from GC analysis of 8-
DHC (31) was detected in only 5 of 16 samples from SLOS
patients (31%), it was identified as 19-nor-cholestatrienol by
mass spectrum, and its concentration ranged from 0.2 to 6.7
mg/dL. Forty-four percent of the SLOS patients (7/16) had
CHOL concentrations lower than 2.5%ile (37.1 mg/dL) of
the reference values, while the remaining 56% (9/16) had
concentrations ranging from 39.9 to 194.6 mg/dL, which was
within the reference values of unaffected subjects. Even
though CHOL concentrations show wide individual varia-
bility, the average values for SLOS and unaffected subjects
were significantly different (ps0.002). In contrast, the con-
centrations of lathosterol and plant sterols in plasma samples
of SLOS and unaffected subjects were not statistically
different.
EM samples (ns15) of SLOS patients stored at –208C for
a variable time, ranging from 1 to 20 months, were analyzed.
The EM samples were isolated from different blood samples
of nine SLOS patients collected at different times during the
period of this study (three samples from patient "6, two
samples from patients "2, "3, "8, "9 and one sample from
patients "4, "10, "11, "14) (Table 3). In order to obtain a
normal EM sterol profile, we analyzed EM samples of
unaffected subjects accepted in 2010 (ns20). As shown in
Table 3, CHOL concentrations in EM of SLOS samples are
on average 3-fold lower than unaffected subjects (p-0.001),
and the DHC concentrations are on average 55-fold higher
in SLOS patients than in unaffected subjects (p-0.01). The
average of DHC/CHOL ratio in EM of SLOS patients was
0.16 and was at least 200-fold higher than unaffected
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Figure 1 Typical GC-MS total ion chromatograms of sterols in plasma of an unaffected subject (A), and SLOS (B), lathosterolosis (C)
and CDPX2 (D) patients.
1: IS; 2: CHOL; 3: 8-DHC; 4: 7-DHC; 5: lathosterol; 6: 8(9)-cholestenol.
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Table 1 Main clinical findings of the study population.
Organ % Clinical findings
Brain 53 Holoprosencephaly, microcephaly, agenesis of the corpus callosum, convulsion, psycomotor retardation
Craniofacial 41.3 Ptosis, anteverted nares, micrognathia, broad nasal bridge, hypertelorism
Acral 39.2 Syndactyly, hypotonia, hypertonia, hypoplasia
Liver 13 Liver disease, icterus
Eye 13 Cataracts, microphthalmia
Heart 10.8 Heart arrhythmia, hypertrophic cardiomyopthy, atrial septal defect
Genitalia 4.4 Genital malformations, precocious puberty
Bowel 4.4 Short bowel syndrome, inguinal hernia
Oral 4.3 Cleft palate
Lung 2.2 Bronchopulmonary dysplasia
Kidney 2.2 Ectopic kidney
Table 2 Plasma sterol profiles by GC-MS in samples from Smith-Lemli-Opitz patients (ns16) compared to unaffected subjects (ns276).
Patients Age, Sex CHOL 8-DHC 7-DHCa Lathosterol Campesterol Stigmasterol Sitosterol DHC/CHOL
years (mgØdL-1)b
SLOS patients
"1 6 M 28.9 2.1 4.9 0.25 0.31 0.07 0.16 0.24
"2 1 M 80.4 14.2 14.3 0 0 0 0 0.35
"3 22 F 11.2 3.0 7.2 0.69 0.04 0.07 0.06 0.91
"4 2 F 194.6 7.3 3.8 0.16 0.22 0.02 0.16 0.06
"5 0.1 M 9.0 5.1 6.9 0 0 0 0 1.33
"6 14 F 134.1 21.0 34.1 0.30 0.10 0.09 0.10 0.41
"7 9 M 24.3 2.4 2.3 0 0 0 0 0.19
"8 7 M 39.9 4.3 6.2 0.20 0.51 0.10 0.39 0.26
"9 15 M 160.6 18.8 28.9 0.84 0.14 0.02 0.02 0.30
"10 15.1 M 57.2 7.7 11.5 0 0 0 0 0.34
"11 10 F 123.2 9.5 12.9 0.32 0.12 0.14 0.10 0.18
"12 0.6 F 8.8 21.4 34.2 0 0 0 0 6.32
"13 3.8 F 89.7 11.6 11.7 0 0 0 0 0.26
"14 0.1 F 45.2 10.0 10.2 0.22 0.10 0.05 0.07 0.45
"15 0.2 M 26.8 8.8 11.2 0.32 0.15 0.14 0.13 0.75
"16 0.04 F 9.6 9.9 15.7 0 0 0 0 2.67
Average (SD) 6.6 (6.9) 65.2 (59.3)c 9.8 (6.3) 13.5 (10.2)d 0.21 (0.25) 0.11 (0.14) 0.04 (0.05) 0.07 (0.10) 0.94 (1.17)e
Unaffected subjects
Rangef 0.02–11 37.1–217.4 -0.10 -0.19 -0.25 -0.33 -0.15 -0.39 -0.002
0: less than the detection limit (LODs0.01). a7-DHCqdesmosterol contribution to ion m/z 325 abundance. bSLOS sterol concentrations
correspond to the first determination. cps0.0002 vs. unaffected subjects. dp-0.0001 vs. unaffected subjects. ep-0.05 vs. unaffected subjects.
frange is reported as 2.5%ile–97.5%ile for age and CHOL, and -95%ile for the other sterols and DHC/CHOL ratio.
Conversion factors to SI units (mg/dL=Factorsmmol/L) are: 0.0259 for Cholesterol and Lathosterol; 0.0260 for 7- and 8-DHC; 0.0250
for Campesterol; 0.242 for Stigmasterol; 0.241 for Sitosterol.
subjects. In SLOS samples, the DHC/CHOL ratio decreased
during storage. As depicted in Figure 2A, the regression
analysis performed between the DHC/CHOL ratio and stor-
age time depicts a significant linear negative correlation
(slopes–0.0223; rs0.598; p-0.01). Furthermore, the DHC/
CHOL ratio in plasma of SLOS samples (Figure 2B; ns12)
analyzed within 24 h and after a variable period of storage,
ranging from 4 to 22 months, also showed a significant linear
negative correlation with the storage time (slopes–0.0098;
rs0.449; p-0.025). Based on these results in SLOS sam-
ples stored at –208C, the rate at which the DHC/CHOL ratio
in EM decreases during storage is at least 2-fold higher than
the decrease observed in plasma samples.
Discussion
In this study, we report our experience over the last six years
in the diagnosis of CHOL biosynthesis defects. Over this
period, we investigated the sterol profile in plasma samples
from 294 patients using GC-MS. Among these patients we
reported 16 affected by SLOS, of which 13 had been pre-
viously identified (from 1995 to 2004), and three were new
SLOS cases. In addition, we identified a new case of CDPX2
in 2009. The plasma sterol profile of the CDPX2 patient,
consistent with previous studies, showed an abnormal pres-
ence of 8(9)-cholestenol, and because of the variability of
CDPX2 clinical manifestations, the biochemical determina-
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Table 3 CHOL and DHC concentrations in EM samples (ns15) from SLOS and unaffected subjects (ns20) analyzed after different
storage times.
Patients CHOL, mgØg prot-1 DHC, mgØg prot-1 DHC/CHOL Storage time, months
SLOS patients
"2 (Sample 1) 53.3 6.49 0.12 11
"2 (Sample 2) 43.9 4.45 0.10 4
"3 (Sample 1) 21.6 0.73 0.03 19
"3 (Sample 2) 13.7 0.84 0.06 13
"4 (Sample 1) 124.4 2.05 0.02 14
"6 (Sample 1) 17.1 0.63 0.04 20
"6 (Sample 2) 17.0 3.61 0.21 11
"6 (Sample 3) 17.3 15.63 0.90 1
"8 (Sample 1) 36.0 0.45 0.01 18
"8 (Sample 2) 56.0 4.07 0.07 10
"9 (Sample 1) 26.5 5.23 0.20 14
"9 (Sample 2) 28.9 2.89 0.10 4
"10 (Sample 1) 59.2 22.88 0.39 5
"11 (Sample 1) 19.6 1.24 0.06 19
"14 (Sample 1) 89.6 2.88 0.03 7
Average (SD) 41.6 (31.3)a 4.94 (6.24)b 0.16 (0.23)c 11 (6)
Unaffected subjects
Average (SD) 123.6 (39.2) 0.09 (0.11) 0.7Ø 10-3 (0.8Ø10-3) 6 (3)
ap-0.001 vs. unaffected subjects. bp-0.01 vs. unaffected subjects. cp-0.025 vs. unaffected subjects.
Figure 2 Correlation between the storage time and DHC/CHOL
ratio in EM (panel A: ys–0.0223xq0.409; rs0.598; p-0.01;
ns15) and plasma samples of SLOS (panel B: ys–0.0098xq
0.430; rs0.449; p-0.025; ns12).
tion of 8(9)-cholestenol in plasma samples of suspected
patients is required to confirm the diagnosis (17).
In this study, we identified three new SLOS cases from
280 suspected patients (1.08%). Kelley et al. reported results
from the two laboratories that perform at least 80% of the
biochemical testing for SLOS in the USA; they identified 40
new cases per year between 1995 and 1998, estimating an
incidence of -1 in 60,000 births (8). Although our labora-
tory is recognized for the diagnosis of CHOL biosynthesis
defects, the SLOS incidence cannot be evaluated accurately
from our data, since the study population consisted of a
limited number of suspected patients coming from Italian
pediatric units. Besides, as previously reported, the SLOS
incidence biochemically confirmed is lower than the
estimates based on known carrier rates of DHCR7 mutations
in the general population. This discrepancy is due to the
difficulty in diagnosing of SLOS cases at either extreme of
the clinical spectrum, such as cases resulting in prenatal and
neonatal deaths and cases of mild/atypical SLOS in surviving
children, and prenatal mortality for the most severely affect-
ed cases of SLOS may be as high as 80% (15, 32). The
clinical signs in diseases caused by defects of CHOL bio-
synthesis are multiple and variable. These signs are generally
present at birth but may only be revealed some years after
birth. The 280 patients investigated for the first time in this
study showed the typical SLOS clinical findings described
by Kelley et al. (8), although SLOS was only confirmed in
1.08% of these subjects and CDPX2 in only 0.4% of the
subjects. The remaining patients were unaffected by CHOL
biosynthesis defects, and this result underlines the impor-
tance of sterol profile analysis for the diagnosis of SLOS and
other defects of CHOL biosynthesis.
In this work, the sterol concentrations in plasma samples
of SLOS and unaffected subjects were in agreement with the
literature, even though, compared to that reported by Kelley,
our 7-DHC reference values were overestimated due to des-
mosterol co-eluting with 7-DHC (24, 30). Studies on refer-
ence values for plasma CHOL are generally focused on the
upper limit of the reference range, and very few data are
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available for the lower limit of CHOL reference values in
plasma of children stratified by age. Lockitch et al. deter-
mined age-related reference value for serum CHOL in 450
healthy children aged from 1 to 19 years (33), and in the age
group from 1 to 3 years they found a value of 44.5 mg/dL
(1.15 mmol/L) at the 2.5%ile. In contrast, the 2.5%ile in our
unaffected subjects was 37.1 mg/dL, and the difference could
be due to differences in age, health status and ethnic origin
between the two study populations.
In plasma samples from five of SLOS patients we detected
a peak corresponding to 19-nor-cholestatrienol, and its level,
as percentage of total sterols, ranged from 0.3% to 3.4%.
The presence of this metabolite is in agreement with other
studies (31, 34), and as demonstrated by Ruan et al. this
sterol is a GC artifact of samples containing 8-DHC and not
a component of normal or SLOS blood (31). Elevated DHC
concentrations in plasma and tissues are considered diagnos-
tic markers of SLOS, and CHOL levels lower than reference
values are considered a marker of SLOS or of other CHOL
biosynthesis defects. Only 44% of the SLOS patients in our
study had CHOL concentrations lower than 2.5%ile of the
reference values obtained in our study or those reported by
Lockitch et al. (33). Furthermore, previous studies have
found that plasma of SLOS patients measured with the enzy-
matic assay may give total CHOL values close to the lower
limit or within the reference ranges of healthy subjects (30).
These observations suggest that some SLOS patients might
be undiagnosed if diagnosis is based only on the enzymatic
measurement of CHOL rather than the sterol profile.
Our method also allows the detection of plant sterols and
definition of their reference values. Plant sterols are present
in small and similar amounts in unaffected subjects and
SLOS patients. The determination of plant sterol reference
values is important because the concentration of these sterols
is increased in sitosterolemia, an inherited defect of lipid
metabolism, characterized by abnormal intestinal absorption
of CHOL and plant sterols (35).
In order to evaluate the effects of storage on the stability
of the CHOL metabolites, we analyzed CHOL and DHC
concentrations in plasma and EM samples of SLOS patients
and unaffected subjects at different times after storage at
–208C. DHC concentrations and DHC/CHOL ratios in the
plasma of SLOS patients were still significantly elevated
after storage at –208C, although they showed on average a
40% reduction after 22 months. After a similar period of
storage (20 months), the DHC/CHOL ratios in EM decreased
on average by 88%. The average DHC level in EM, as
percentage of the total sterols, was 5-fold lower than that
reported by Tint et al. (3), using fresh EM samples from
SLOS patients. In addition, the DHC/CHOL ratio reported
in our study is 4- to 8-fold lower than the values reported in
EM samples from two SLOS patients analyzed by Jira et al.
(36). The regression analysis between the DHC/CHOL ratio
and storage time showed a significant negative linear cor-
relation (p-0.01), which confirms the high instability of
DHC in EM samples during storage, and is in agreement
with a previous study performed using dried blood spots
(26). In addition, as recently reported by Xu et al. the insta-
bility of 7-DHC in solution and in liposomes is due to its
susceptibility to peroxidation, which is at least 10-fold more
reactive than arachidonic acid, a polyunsaturated fatty acid
that is normally considered to be a highly oxidizable lipid,
and at least 200-fold more reactive than cholesterol (37).
Based on these results, the instability of DHC should be pre-
vented by adding antioxidants in plasma and EM to stabilize
lipids during the storage and the analytical procedure. The
study of antioxidant effects, added to blood, plasma, and
other biological fluids, on DHC peroxidation merit further
research. Our study highlights the need among obstetricians,
neonatologist, and other healthcare providers for increased
awareness of the various presentations of SLOS in the fetal
and newborn periods in order to diagnose this condition
effectively. The analysis of sterol profiles should be required
for all patients showing suspect clinical features suggestive
of CHOL biosynthesis defects. In addition, the effect of stor-
age time on DHC concentrations in plasma and EM, and the
resultant possibility of false-negative results, should be taken
into account when interpreting the results.
Finally, considering that SLOS is the most frequent of the
CHOL biosynthesis defects and its prevalence has not yet
been accurately determined, further work should be directed
to implement new high-throughput methods for the meas-
urement of DHC in dried blood spots. These methods, based
on tandem mass spectrometry or other approaches, could rep-
resent useful tools for newborn screening of this syndrome (38).
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